Akorn, Inc.
270 articles with Akorn, Inc.
-
Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Products Expanding its Presence in the United States Eye Care Industry
3/9/2022
Théa Pharma Inc. announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC.
-
Akorn Announces Completion of the Sale of its Branded Ophthalmic Products to Théa Pharma
3/9/2022
Akorn Operating Company LLC, a leading specialty pharmaceutical company, announced the completion of its previously announced sale of seven branded ophthalmic products to Théa Pharma.
-
Akorn Announces Agreement to Sell its Branded Ophthalmic Products to Théa
1/28/2022
Akorn Operating Company LLC announced today that it has entered into a definitive agreement to sell seven branded ophthalmic products to Théa.
-
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
-
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
2/11/2021
Akorn Operating Company LLC (Akorn), a leading specialty pharmaceutical company, announced that it received approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Loteprednol Etabonate Ophthalmic Gel, 0.5%.
-
Akorn Announces Its New Board of Directors
10/28/2020
Akorn, a leading specialty pharmaceutical company, today announced the appointment of its new Board of Directors. "Akorn's new shareholders have appointed a strong board of independent pharmaceutical industry and finance professionals with a mandate to steward the Company towards long-term value creation," said Robert Webst
-
Akorn Successfully Completes Sale to Lenders and Exits Chapter 11 Protection
10/2/2020
Company positioned to enter its next phase of growth with new ownership and a more sustainable capital structure
-
Akorn Receives Court Approval of Sale to Lenders
9/2/2020
Akorn, Inc., a leading specialty pharmaceutical company, announced that the United States Bankruptcy Court for the District of Delaware has approved its sale to the Company's existing lenders.
-
Akorn Provides Second Quarter 2020 Results
8/7/2020
- Akorn, Inc. (The OTC Pink Market: AKRXQ), a leading specialty pharmaceutical company, today announced its financial results for the second quarter of 2020. Second Quarter 2020 Results and Recent Developments Net revenue was $120 million, down $58 million, 32% from the prior year quarter Net loss was $69 million, compared to $112 million loss in the prior year quarter Adjusted EBITDA was $(2) million, compared to $36 million in the pr
-
Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment
6/22/2020
Akorn, Inc., a leading specialty generic pharmaceutical company, announced the launch of its Abbreviated New Animal Drug Application for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP.
-
Two years after Germany’s Fresenius Medical Care walked away from a 2017 $4.3 billion deal to acquire Akorn Pharmaceuticals, the company has filed for protection under U.S. bankruptcy laws as it attempts to restructure for a potential sale.
-
Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
5/21/2020
Continues Operations as Usual, Delivering Safe and Effective Products to Customers and Patients
-
Akorn Provides First Quarter 2020 Results
5/11/2020
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the first quarter of 2020.
-
Akorn Provides Update on Sale Process
4/1/2020
Akorn, Inc. announced that it no longer has any bids in the Sale Process that are sufficient to pay all obligations under its term loan agreement.
-
Akorn Provides Fourth Quarter and Full Year 2019 Results
2/26/2020
Akorn, Inc., a leading specialty pharmaceutical company, announced its financial results for the quarter and year ended December 31, 2019.
-
Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business
2/12/2020
Akorn, Inc., a leading specialty pharmaceutical company, announced it has reached an agreement with certain of its lenders to extend the standstill period.
-
Akorn Continues Negotiations with Lenders
2/10/2020
Akorn, Inc. confirmed that negotiations with certain of its lenders are ongoing following the expiration of its standstill agreement on February 7, 2020.
-
Akorn Announces Extension of Standstill Agreement
12/16/2019
Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that Akorn and certain of its lenders have reached an agreement that extends the standstill period to February 7, 2020.
-
Akorn to Present at the Credit Suisse Healthcare Conference
11/6/2019
Akorn, Inc., a leading specialty pharmaceutical company, announced that management will present at the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019 at 10:55 a.m. Mountain Time, in Scottsdale, Arizona..
-
Akorn Provides Preliminary Third Quarter 2019 ResultsUpdates net loss and affirms net revenue and adjusted EBITDA guidance
10/31/2019
Akorn, Inc., a leading specialty pharmaceutical company, announced its preliminary financial results for the third quarter of 2019.